TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01051245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case manager counseling
Description: Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
Study: NCT01397253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated communication tools
Description: Automated communication tools will include:~* PCP notification of patient admission and location~* Data on medications begun on admission~* Automated alerts on changes in patient status and location while the patient is hospitalized~* Links to the EMR and to hospital physician contact information on all email alerts~* Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP~* Automatic reporting to PCPs of test results pending at discharge~* Electronic delivery of final discharge summaries
Study: NCT03906526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX-2337
Description: Motolimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX-2337
Description: Motolimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX-2337
Description: Motolimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV Nivolumab
Study: NCT02581072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 8% or 12%
Description: Applied once topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Applied topically once
Study: NCT04667247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FoTv
Description: 8 capsules three times a day for 14 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FoTv
Description: 8 capsules three times a day for 14 consecutive days.
Study: NCT00500006

Intervention type: DRUG
Group type: OTHER
Intervention: MK0457
Description: Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour.

Intervention type: DRUG
Group type: OTHER
Intervention: MK0457
Description: Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour.

Intervention type: DRUG
Group type: OTHER
Intervention: dasatinib
Description: Oral dasatinib 70 mg b.i.d. tablets twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: dasatinib
Description: Oral dasatinib 70 mg b.i.d. tablets twice daily.
Study: NCT04628936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KZR-616
Description: Subcutaneous 30 mg for 1 week, then 45 mg weekly
Study: NCT04625075

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI with gadolinium and manganese contrast
Study: NCT01255046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil,
Description: 10mg/tab, 1 tab/day for 72 weeks
Study: NCT04013646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo erythropoietin injection
Description: Placebo erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
Study: NCT04242680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainstim DLPFC
Description: The active tRNS will be delivered to bilateral DLPFC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right DLPFC, F3 and F4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75 milliampere (mA) (100-500 Hz), the duration of stimulation will be 20 min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainstim PPC
Description: The active tRNS will be delivered to bilateral PPC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right PPC, P3 and P4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75mA (100-500 Hz), the duration of stimulation will be 20 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brainstim Sham
Description: The same electrode placement will be used as in the stimulation conditions (Brainstim DLPFC or Brainstim PPC), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held five consecutive days for two weeks for a total of ten days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: A cognitive training (Vektor; Nemmi et al., 2016) will be adiministered concomitantly to Brainstim DLPFC, Brainstim PPC, Brainstim Sham for 20 min.~The training consisted of math exercises (number line, calculations) and math-related exercises (visuo-spatial working memory, mental rotation).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: A cognitive training (Vektor; Nemmi et al., 2016) will be adiministered concomitantly to Brainstim DLPFC, Brainstim PPC, Brainstim Sham for 20 min.~The training consisted of math exercises (number line, calculations) and math-related exercises (visuo-spatial working memory, mental rotation).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: A cognitive training (Vektor; Nemmi et al., 2016) will be adiministered concomitantly to Brainstim DLPFC, Brainstim PPC, Brainstim Sham for 20 min.~The training consisted of math exercises (number line, calculations) and math-related exercises (visuo-spatial working memory, mental rotation).
Study: NCT04667689

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CAMPFIRE Online Cognitive Assessment for Cancer Patients
Description: Subjects will complete PROMIS Cognitive Function/Anxiety/Depression survey assessments and a short neuropsychological battery (NIH Toolbox) on an iPad while in clinic prior to beginning chemotherapy, again before a clinic visit scheduled between 6 - 9 weeks and, lastly, before a post-chemotherapy follow-up clinic visit. Within two weeks of their post-chemotherapy assessment, subjects will be asked to complete a feedback survey. The physician providers and/or their clinical team (e.g., nurse practitioners, registered nurses) will be asked to review subjects' cognitive assessment results and discuss referrals and/or recommendations, if appropriate.
Study: NCT04630483

Intervention type: OTHER
Intervention: INHA
Description: NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values

Intervention type: OTHER
Intervention: TIVA
Description: NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
Study: NCT01255046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil,
Description: 10mg/tab, 1 tab/day for 72 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STA-1
Description: 300mg/tab, 2 tab/tid for 72 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tab/tid for 72 weeks
Study: NCT02405234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Modular Radial Head replacement
Description: 'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal Radial Head replacement
Description: Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
Study: NCT02477722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFP-NF

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT00731393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thiomersal free trivalent influenza split vaccine 2003/2004
Description: 2 doses, intramuscular injection
Study: NCT04625075

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI with gadolinium and manganese contrast

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI with gadolinium and manganese contrast

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac CT
Description: Cardiac CT to assess coronaries

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac CT
Description: Cardiac CT to assess coronaries

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram (ECG)
Description: ECG to assess rhythm

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram (ECG)
Description: ECG to assess rhythm

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram (ECG)
Description: ECG to assess rhythm

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: renal function liver function full blood count, hematocrit glucose

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: renal function liver function full blood count, hematocrit glucose

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: renal function liver function full blood count, hematocrit glucose
Study: NCT04013646

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Active rehabilitation
Description: Physical therapy and occupational therapy are performed daily.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active rehabilitation
Description: Physical therapy and occupational therapy are performed daily.
Study: NCT00731393

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004
Description: 2 doses, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004
Description: 2 doses, intramuscular injection
Study: NCT04013646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active rehabilitation
Description: Physical therapy and occupational therapy are performed daily.
Study: NCT01692730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Web Assisted Tobacco Intervention
Description: Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Web Assisted Tobacco Intervention
Description: Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
Study: NCT02298751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Exposure Treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Exposure Treatment
Study: NCT01382030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIA chemotherapy
Description: ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1
Study: NCT00003292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study: NCT03297372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation
Description: Implantation of monofocal IOL Micropure 1.2.3
Study: NCT00437190

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATLANTIS™ Cervical Plate System and allograft
Description: Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRYAN Cervical Disc Prosthesis
Description: The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
Study: NCT03050099

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
Study: NCT00967603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: oral sunitinib 37.5 mg daily
Study: NCT00410683

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study: NCT04218981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs
Description: Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mood stabilizer
Description: Choose lithium or valproate for bipolar disorder group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Patients with major depressive disorder are treated with paroxetine
Study: NCT04394494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery. Imaging doing Extension exercises without actually doing them.
Description: This study will compare imagining doing specific extension based exercises for LBP vs. actually performing the exercises. This intervention will be just imaging doing the exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Physically performing extension based exercises.
Description: This study will compare imagining doing specific extension based exercises for LBP vs. actually doing them. This intervention will be actually, physically performing the exercises.
Study: NCT00078260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: A: 500 mg/m2, IV, q 21 days until disease progression~B: 900 mg/m2, IV, q 21 days until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: A: 500 mg/m2, IV, q 21 days until disease progression~B: 900 mg/m2, IV, q 21 days until disease progression
Study: NCT02399293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: N-back
Description: The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: N-back
Description: The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual Search
Description: The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual Search
Description: The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day.
Study: NCT02746315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20004
Study: NCT02378155

Intervention type: DEVICE
Group type: OTHER
Intervention: SenSmart Model X-100, Nonin Medical
Description: Device to measure cerebral tissue oxygen saturation

Intervention type: DEVICE
Group type: OTHER
Intervention: SenSmart Model X-100, Nonin Medical
Description: Device to measure cerebral tissue oxygen saturation
Study: NCT03856099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTAC-0001
Description: * Investigational product (IP): TTAC-0001~* Treatment groups: 3 dose groups~  * Dose group A : TTAC-0001 16 mg/kg on D1 and D15~ * Dose group B : TTAC-0001 20 mg/kg on D1 and D15~ * Dose group C : TTAC-0001 24 mg/kg on D1 and D15~* Cycle: 4 weeks (28 days per cycle)
Study: NCT02181660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: oral
Study: NCT00611897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine and ketamine
Description: Active drug (N-acetylcysteine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo and ketamine
Description: placebo N-acetylcysteine
Study: NCT04310150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collastat
Description: hemostatic agent that combine porcine-derived collagen thrombin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Floseal
Description: hemostatic agent that combine bovine-derived gelatin
Study: NCT02746315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02793960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical BPM31510 3.0% Cream
Description: Application of drug to lesions of epidermolysis bullosa
Study: NCT05136716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Stretching for tight muscles, strengthening for weak muscles, postural reactions training, proprioceptive training, and walking training were all part of the neurodevelopmental treatment plan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: HBO2 therapy at a pressure of 1.7 atm For 60 minutes, participants breathed 100% O2.
Study: NCT01882816

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DWI MRI
Description: The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Barium Swallow Impairment Profile (MBSImP)
Description: The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.